ClinicalTrials.gg
CompletedNCT00056368Updated Oct 21, 2008

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

A Phase 3 interventional study of Anidulafungin and Fluconazole in Candidiasis, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2008-10-21.

Primary conditionCandidemiaRegistry: CandidiasisReclassifiedWhy we changed it
Registry
Candidiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Candidemia
Why
  1. The study's title name Candidemia, a narrower term within Candidiasis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing anidulafungin in Candidemia — none open to participants now, none under way, none of them phase 3. Anidulafungin · Candidemia.

Enrollment
2nd of 11
256 · median 70
Started
2003
the only one that year
Phase 3
5 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
9 of 11
Pfizer

Among the 11 studies testing anidulafungin in Candidemia, this one is the 2nd largest by enrollment, is the only one that started in 2003, is one of 5 in phase 3, and was the 2nd registered.

Candidemia

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

Browse Candidemia studies →

Open to participants now

None of the 11 studies testing anidulafungin in Candidemia is open now. The open studies under Candidemia, anywhere →

About anidulafungin

Anidulafungin: first FDA approval 2006 (ERAXIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing anidulafungin in Candidemia as a file.
02

Study summary

Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.

Read the detailed description

Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.

03

Conditions studied

  • Candidiasis

Browse trials for

Keywords

  • Candida blood stream infections
  • Candida infections
  • Candidemia
  • Invasive Candidiasis
04

In context

Candidemia Reclassified

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

This study's enrollment of 256 is above the median of 63 across 44 interventional studies indexed under Candidemia.

Browse Candidemia studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Candidemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Candidiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Diagnosis of candidemia and/or other forms of invasive candidiasis.
  • Should not have received greater than 48 hours of systemic antifungal therapy.
  • should be greater than 72 hours.
  • Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
256 participants (actual)

Interventions

07

Study locations

1 site
  • Versicor, Inc.
    King of Prussia, Pennsylvania 19406, United States
08

References and documents

Publications

  • Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 Jun 14;356(24):2472-82. doi: 10.1056/NEJMoa066906. PubMed 17568028 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2003
First posted
Mar 12, 2003
Start
Mar 2003
CompletionActual
Oct 2004
Last update
Oct 21, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00056368
Lead sponsor
Pfizer
Collaborators
Vicuron Pharmaceuticals
First posted
Mar 12, 2003
Start date
Mar 2003
Completion
Oct 2004
Last update
Oct 21, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anidulafungin · Fluconazole

Start the discussion